Acrivon Therapeutics (ACRV) Stock Forecast, Price Target & Predictions
ACRV Stock Forecast
Acrivon Therapeutics stock forecast is as follows: an average price target of $21.83 (represents a 248.17% upside from ACRV’s last price of $6.27) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
ACRV Price Target
The average price target for Acrivon Therapeutics (ACRV) is $21.83 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $17.00. This represents a potential 248.17% upside from ACRV's last price of $6.27.
ACRV Analyst Ratings
According to 7 Wall Street analysts, Acrivon Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ACRV stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Acrivon Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | Etzer Darout | BMO Capital | $27.00 | $7.92 | 240.91% | 330.62% |
| Sep 16, 2024 | Etzer Darout | BMO Capital | $28.00 | $8.91 | 214.25% | 346.57% |
| Aug 13, 2024 | Matthew Biegler | Oppenheimer | $18.00 | $7.26 | 147.93% | 187.08% |
| May 14, 2024 | Matthew Biegler | Oppenheimer | $21.00 | $8.36 | 151.20% | 234.93% |
| May 14, 2024 | Emily Bodnar | H.C. Wainwright | $22.00 | $8.35 | 163.63% | 250.88% |
| May 14, 2024 | Etzer Darout | BMO Capital | $25.00 | $8.51 | 193.77% | 298.72% |
| Apr 25, 2024 | Joseph Catanzaro | Piper Sandler | $30.00 | $9.20 | 226.09% | 378.47% |
| Apr 25, 2024 | Silvan Tuerkcan | JMP Securities | $17.00 | $9.50 | 78.95% | 171.13% |
| Mar 28, 2024 | Emily Bodnar | H.C. Wainwright | $20.00 | $7.18 | 178.36% | 218.98% |
| Dec 12, 2022 | - | Jefferies | $17.00 | $12.50 | 36.00% | 171.13% |
The latest Acrivon Therapeutics stock forecast, released on Nov 14, 2024 by Etzer Darout from BMO Capital, set a price target of $27.00, which represents a 240.91% increase from the stock price at the time of the forecast ($7.92), and a 330.62% increase from ACRV last price ($6.27).
Acrivon Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 9 |
| Avg Price Target | $27.00 | $27.50 | $23.11 |
| Last Closing Price | $6.27 | $6.27 | $6.27 |
| Upside/Downside | 330.62% | 338.60% | 268.58% |
In the current month, the average price target of Acrivon Therapeutics stock is $27.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 330.62% increase as opposed to Acrivon Therapeutics's last price of $6.27. This month's average price target is down -1.82% compared to last quarter, and up 16.83% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 16, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 13, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Apr 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Acrivon Therapeutics's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave ACRV a "Buy" rating, the same as its previous rate.
Acrivon Therapeutics Financial Forecast
Acrivon Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $1.15M | - | - | - | - | - | - |
| High Forecast | $1.15M | - | - | - | - | - | - |
| Low Forecast | $1.15M | - | - | - | - | - | - |
| # Analysts | 1 | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Acrivon Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ACRV's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Acrivon Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ACRV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Acrivon Therapeutics's previous annual EBITDA (undefined) of $NaN.
Acrivon Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-27.53M | $-27.72M | $-25.93M | $-25.17M | $-25.68M | $-22.04M | $-21.77M |
| High Forecast | $-27.53M | $-27.72M | $-25.93M | $-25.17M | $-22.83M | $-22.04M | $-21.77M |
| Low Forecast | $-27.53M | $-27.72M | $-25.93M | $-25.17M | $-27.31M | $-22.04M | $-21.77M |
| Surprise % | - | - | - | - | - | - | - |
Acrivon Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACRV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Acrivon Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Acrivon Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ACRV last annual SG&A of $NaN (undefined).
Acrivon Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.72 | $-0.73 | $-0.68 | $-0.66 | $-0.67 | $-0.58 | $-0.60 |
| High Forecast | $-0.72 | $-0.73 | $-0.68 | $-0.66 | $-0.60 | $-0.58 | $-0.60 |
| Low Forecast | $-0.72 | $-0.73 | $-0.68 | $-0.66 | $-0.72 | $-0.58 | $-0.60 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Acrivon Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACRV previous annual EPS of $NaN (undefined).
Acrivon Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.56 | $18.00 | 1053.85% | Buy |
| ANTX | AN2 Therapeutics | $1.00 | $8.75 | 775.00% | Buy |
| AVTE | Aerovate Therapeutics | $2.53 | $13.00 | 413.83% | Hold |
| MOLN | Molecular Partners | $5.83 | $29.00 | 397.43% | Buy |
| OPT | Opthea | $3.26 | $14.00 | 329.45% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.53 | $6.00 | 292.16% | Buy |
| ACRV | Acrivon Therapeutics | $6.27 | $21.83 | 248.17% | Buy |
| RZLT | Rezolute | $4.87 | $13.50 | 177.21% | Buy |
| ANAB | AnaptysBio | $18.88 | $52.00 | 175.42% | Buy |
| MLYS | Mineralys Therapeutics | $11.40 | $30.00 | 163.16% | Buy |
| ADAG | Adagene | $2.24 | $5.00 | 123.21% | Buy |